Ask Jacki About Health, Stem Cells & Changing Lives


Stem Cell Scientists Make Case For More Research To Defeat Diseases

Over the last few years more scientists are learning what Christian Drapeau and STEMTech have known for years….that adult stem cells make up our bodies renewal system and we can naturally increase their numbers by taking Stem Enhance. Increase your circulating stem cells for optimal health.

Leading stem cell scientists make an impassioned case for renewing humanity and defeating disease.

Blood Stem-Cell Transplant Regimen Reverses Sickle Cell Disease in Adults

Blood Stem-Cell Transplant Regimen Reverses Sickle Cell Disease in Adults

 A modified blood adult stem-cell transplant regimen has effectively reversed sickle cell disease in 9 of 10 adults who had been severely affected by the disease, according to results of a National Institutes of Health study in the Dec. 10 issue of the New England Journal of Medicine. The trial was conducted at the NIH Clinical Center in Bethesda, Md., by NIH researchers at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases.

“This trial represents a major milestone in developing a therapy aimed at curing sickle cell disease,” said NIDDK Director Griffin P. Rodgers M.D., a co-author of the paper. “Our modified transplant regimen changes the equation for treating adult patients with severe disease in a safer, more effective way.”

Sickle cell disease is caused by an altered gene that produces abnormal hemoglobin, the protein in normal red blood cells that carries oxygen throughout the body. When affected red cells lose oxygen, they collapse into a sickle, or C, shape and become stiff and sticky. Clumps of these cells block blood flow and can cause severe pain, organ damage from lack of oxygen, and stroke. Anemia often develops in people with the disease because sickle cells die off quickly and bone marrow does not make new ones fast enough.

In trials by other investigators, nearly 200 children with severe sickle cell disease were cured with bone marrow transplants after undergoing a regimen in which their own marrow was completely destroyed with chemotherapy. That regimen, however, had proven too toxic for adults, who have years of accumulated organ damage from the disease and are less able to tolerate complete marrow transplantation.

In contrast to the established method in children, this adult trial sought to reduce toxicity by only partially replacing the bone marrow. The much longer lifespan of normal red blood cells, compared to sickle red blood cells, allows the healthy cells to outlast and completely replace the disease-causing cells.

To achieve this goal, the investigators used a low dose of radiation to the whole body and two drugs, alemtuzumab and sirolimus, to suppress the immune system. Alemtuzumab depletes immune cells, but does not adversely affect blood stem cells. Sirolimus does not block the activation of immune cells, but inhibits their proliferation, creating a balance that potentially helps prevent rejection of the new stem cells.

The radiation favorably conditions the bone marrow, where donor stem cells move in and begin producing new, healthy red blood cells. After a median two and one half years follow-up, all 10 recipients were alive and sickle cell disease was eliminated in nine.

“Our patients have had a remarkable change in their lives,” said John F. Tisdale, M.D., the trial’s principal investigator in the NIH Molecular and Clinical Hematology Branch. “They are no longer being admitted to the hospital for frequent pain crises, they have been able to stop chronic pain medications, go back to school and work, get married and have children. Given these results, our regimen will likely have broad application to other nonmalignant diseases and can be performed at most transplant centers.”

 Transplanted cells or tissue are known as grafts. To reduce the possibility of the immune system’s rejection of the graft or development of graft-versus-host disease, in which immune cells from the donor attack the recipient’s tissues, investigators tested the patient and the potential donor to determine if they are a good immunological match. This is called human leukocyte antigen (HLA) typing.

The investigators performed HLA typing on 112 people with severe sickle cell disease and 169 healthy siblings. Of these, 10 patient-sibling identical matches were found. Blood stem cells collected from the blood of healthy donors were then infused into their siblings, ages 16 to 45 years.

This relatively low toxicity regimen allowed patients to become tolerant to the donor immune cells and to achieve stable mixed donor chimerism. Chimerism is a condition in which an individual has two genetically distinct types of cells in the blood. This mixture of host and donor cells was sufficient to reverse sickle cell disease. In most patients the donor’s red blood cells completely replaced the recipient’s.

“Remarkably, the treatment did not result in graft-versus-host disease for any of the participants,” noted Susan B. Shurin, M.D., acting director of the NHLBI. GVHD is a common complication of stem cell transplantation and can lead to serious problems, such as rash, diarrhea and nausea, liver disease, or death. “We are continuing to explore better treatments with fewer side effects to help the millions of sickle cell patients worldwide. This is a very important study because it lessens the toxicity of a therapy known to be highly effective.”

 In the United States, approximately 80,000 people have sickle cell disease, found mainly in people of African ancestry. It occurs to a lesser extent in people of Hispanic, Middle Eastern, Asian and white ancestry. Worldwide, millions of people have sickle cell disease. The pain and complications associated with sickle cell disease can have a profound impact on patients’ quality of life, ability to work, and long-term health and well-being.

One of the main obstacles in treating a larger number of African-Americans with sickle cell disease is the relative lack of an available HLA-matched donor. Dr. Tisdale explained, “Most white Americans can easily find a matched donor in the unrelated bone marrow or cord blood registries; yet when we screened a number of the people in our trial who were without an HLA-matched sibling donor, we could not find a compatible unrelated donor.”

However, there may be a way beyond this health care disparity, Tisdale indicated. If participants in the current trial continue to do well with their transplants it may be possible to move to what he calls “haplo-transplantation,” or a half-match from a sibling, parent or child. “This would allow most people with sickle cell disease to be treated and enjoy a better quality of life,” he said.

 The NIH Clinical Center’s Department of Laboratory Medicine and Transfusion Medicine provided clinical laboratory and transfusion medicine support and patient care for the stem cell donors and transplantation recipients in trial. The Sidney Kimmel Cancer Center at Johns Hopkins Medical Institute provided conceptual input into the design of the trial’s immunological component. The trial is registered as NCT00061568 in www.clinicaltrials.gov.

Health care providers — and sickle cell patients and family members who may be interested in joining NIH blood stem-cell transplant studies — may call 301-402-6466 for more information. Calls will be returned within 48 hours. To search for other clinical trials, visit www.clinicaltrials.gov.

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

 The NIH Clinical Center (CC) is the clinical research hospital for the National Institutes of Health. Through clinical research, physician-investigators translate laboratory discoveries into better treatments, therapies and interventions to improve the nation’s health. For more information, visit http://clinicalcenter.nih.gov.

Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at: www.nhlbi.nih.gov.

 NIDDK, part of NIH, conducts and supports basic and clinical research and research training on some of the most common, severe and disabling conditions affecting Americans. The Institute’s research interests include: diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition, and obesity; and kidney, urologic and hematologic diseases. For more information, visit www.niddk.nih.gov.

The National Institutes of Health (NIH) — The Nation’s Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

 ——————————————————————————–

More information on sickle cell disease is available at: www.nhlbi.nih.gov/health/dci/Diseases/Sca/SCA_WhatIs.html  and http://diabetes.niddk.nih.gov/dm/pubs/hemovari-A1C/.

For information on blood stem cell transplantation and HLA matching, visit http://www3.niaid.nih.gov/labs/aboutlabs/lhd/geneticImmunotherapySection/malech.htm

Posted at National Institute of Health

http://www.nih.gov/news/health/dec2009/niddk-09.htm

CARDIOVASCULAR REVASCULARIZATION MEDICINE

CARDIOVASCULAR REVASCULARIZATION MEDICINE

SCIENTIFIC STUDIES – 
st-cardio-journalCARDIOVASCULAR REVASCULARIZATION MEDICINE
including Molecular Interventions
Posted January 1, 2008

Abstract – PubMed.gov

Description

Mobilization of human CD34+CD133+ and CD34+CD133%u2212 stem cells in vivo by consumption of an extract from Aphanizomenon flos-aquae-related to modulation of CXCR4 expression by an L-selectin ligand?

This article is not included in your organization’s subscription. However, you may be able to access this article under your organization’s agreement with Elsevier.
Gitte S. Jensen, Aaron N. Hartb, Lue A.M. Zaske, Christian Drapeau, Niraj Guptad, David J. Schaeffere and J. Alex Cruickshank

a. Holger NIS, 601 13 Avenue NE, Calgary, Alberta, Canada T2E 1C7

b. NIS Labs, 1437 Esplanade, Klamath Falls, OR, USA

c. StemTech Health Sciences Inc., 1011 Calle Amanecer, San Clemente, CA, USA

d. Cancer Treatment Center, Merle West Medical Center, 2610 Uhrmann Rd, Klamath Falls, OR, USA

e. Department of Veterinary Biosciences, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, USA

The coauthor C. Drapeau is Chief Science Officer for StemTech Health Sciences, which distributes the product StemEnhance, used for the in vivo part of this paper. No other authors have any commercial interest in the subject matter. Available online 29 August 2007.

Abstract
Objective
The goal of this study was to evaluate effects on human stem cells in vitro and in vivo of an extract from the edible cyanobacterium Aphanizomenon flos-aquae (AFA) enriched for a novel ligand for human CD62L (L-selectin).

Experimental approach
Ligands for CD62L provide a mechanism for stem cell mobilization in conjunction with down-regulation of the CXCR4 chemokine receptor for stromal derived factor 1. Affinity immunoprecipitation was used to identify a novel ligand for CD62L from a water extract from AFA. The effects of AFA water extract on CD62L binding and CXCR4 expression was tested in vitro using human bone marrow CD34+ cells and the two progenitor cell lines, KG1a and K562. A double-blind randomized crossover study involving 12 healthy subjects evaluated the effects of consumption on stem cell mobilization in vivo.

Results
An AFA extract rich in the CD62L ligand reduced the fucoidan-mediated externalization of the CXCR4 chemokine receptor on bone marrow CD34+ cells by 30% and the CD62L+ CD34+ cell line KG1A by 50% but did not alter the CXCR4 expression levels on the CD34 cell line K562. A transient, 18% increase in numbers of circulating CD34+ stem cells maximized 1 hour after consumption (P<.0003). When 3 noncompliant volunteers were removed from analysis, the increase in CD34+ cells was 25% (P<.0001).

Conclusion
AFA water extract contains a novel ligand for CD62L. It modulates CXCR4 expression on CD34+ bone marrow cells in vitro and triggers the mobilization of CD34+ CD133+ and CD34+ CD133 cells in vivo.

Keywords: L-selectin; Ligand; Human; Adult stem cell; CD34; CD133; KG1a; K562; Bone marrow; Mobilization; Blue-green algae; Cyanobacteria; Aphanizomenon; In vivo; In vitro

Abbreviations: AFA, Aphanizomenon flos-aquae; PBMC, Peripheral blood mononuclear cells; PMN, Polymorph-nucleated cells

Article Outline
1. Introduction
2. Materials and methods
2.1. Buffers and media
2.2. Cyanobacterial extracts
2.3. Monoclonal antibodies
2.4. Capturing of ligand using Dynabeads and chimera proteins
2.5. Electrophoresis
2.6. Human subjects
2.7. Immunostaining for L-selectin
2.8. Immunostaining for CXCR4 expression on different types of progenitor cells
2.9. Induction of CXCR4 expression on various types of stem and progenitor-type cells
2.10. Study design for in vivo testing of consumption of an LSL-rich fraction of AFA
2.11. Statistical analysis
3. Results
3.1. AFA contains a ligand for human L-selectin (CD62L)
3.2. AFA-W specifically reduces TQ1 immunostaining of L-selectin on human PMN cells
3.3. AFA-W inhibits the fucoidan-induced CXCR4 expression on CD34+ cells from bone marrow and on the KG1a CD34bright cell line but not on the CD34%u2212 cell line K562
3.4. In vivo: consumption of an AFA extract rich in AFA-LSL resulted in a transient increase of circulating CD34+ cells
4. Discussion

Acknowledgements
References

Download Complete Article Here: http://twurl.nl/2ne65h

Can Adult Stem Cells Be The Answer to Optimal Health?

green-stem-cellI have been researching adult stem cell therapies, clinical trials, journals and scientific literature for the past 16 months. With the abundance of scientific studies and supporting documentation on its many confirmed successes, I find it difficult to still have to debate the use of embryonic stem cells as a viable option. With the amount of evidence piling up supporting adult stem cell therapy maybe soon we will be able to put the debate to rest.

Regenerative medicine using stem cells was listed as one of the Top Research Trends for 2009. Adult stem cells are the answer to our question of how to promote health.

Once the world begins to understand that we have scientific studies documenting the ability to increase the release by 3 to 4 million of our own adult stem cells from the bone marrow into the bloodstream, go to http://tinyurl.com/ajs6gl , using a natural supplement then we will truly begin to realize our future for optimal health starts today.

For more information: http://www.stemcellhotline.com/ or email askjacki@gmail.com

Story of Christian Drapeau MSc. and StemEnhance

christian-drapeau2This is the story of how Christian Drapeau MSc. Chief Science Officer & Co-Founder of StemTech Health Sciences helped develop StemEnhance
A little over two decades ago, a new herbal supplement named Aphanizomenon flos-aquae (AFA), an aquatic botanical, made its appearance on the marketplace. Rapidly, AFA became popular for the wide variety of health benefits reported by consumers. Over the years we identified the presence in AFA of various bioactive compounds such as phycocyanin, a strong natural anti-inflammatory compound, a polysaccharide supporting immune function, and phenylethylamine (PEA), a molecule knows as “the molecule of love,” which increases mental clarity and provides a sense of well-being. Nevertheless, in spite of the identification of these various components, many health benefits reported by consumers remained unexplained.
At the turn of the 21st century, data began appearing in the scientific literature describing the potential of embryonic stem cells (ESC). Embryonic stem cells were shown to have the ability to become any kind of cells in the body. Soon after, studies revealed that adult stem cells (ASC) also had the ability of becoming virtually any kind of cells in the body. When this discovery was made, we hypothesized that adult stem cells constituted the natural renewal system of the body, and we published this hypothesis in the journal, Medical Hypotheses (October 2002). Our idea at the time was this: if adult stem cells indeed constituted the natural renewal system of the body, with adult stem cells being able to become any cell type of the body, then supporting this process could lead to a wide variety of health benefits. Given the broad spectrum of benefits reported by AFA consumers, we simply hypothesized that AFA was supporting aspects of stem cell physiology.
With this in mind, we initiated a series of laboratory experiments and soon discovered that consumption of large quantity of AFA (greater than 5 grams) increased the number of circulating stem cells by up to 30%. As we pursued our investigation to identify the compound in AFA responsible for this effect, we actually identified two specific compounds supporting both the release of stem cells from the bone marrow and their migration out of the blood into tissues. We then proceeded to concentrate these compounds out of AFA, achieving 5:1 concentrates for both compounds, and blended these compounds to make StemEnhance. One gram of StemEnhance supports the release of stem cells from the bone marrow and increases the number of stem cells from the bone marrow and increases the number of circulating stem cells by up to 30%. StemEnhance also concentrates phycocyanin and PEA, other important compounds found in AFA.
StemEnhance is a natural product made of 100% organic AFA and manufactured in accordance with GMP regulations. The powder is encapsulated and bottled in a pharmaceutical grade facility, providing the highest quality possible. Each lot of StemEnhance is tested for any potential contaminants, according to a stringent quality control program.
When asked why would one want to take StemEnhance, the answer is simply to support the body’s natural process of maintaining optimal health. Supporting stem cell physiology everyday by increasing the number of circulating stem cells is one of the wisest decisions one can make to regain and maintain optimal health.
Jacki Smith  – Health Coach 817.510.3600
askjacki@gmail.com   www.stemcellhotline.com

How I Got Started as a Health Coach

My name is Jacki Smith. I am an Alternative Health Consultant. I have been recommending and using dietary supplements for over 20 years. I would like to share my story with you. My mother Beverly Smith, was my inspiration to get into the health and nutrition industry, and network marketing. She started “The Diet Shoppe” business in 1989 and I continue to operate the business as “Natural Health” today.
In 1992, my mother was diagnosed with breast cancer. The surgeon performed a mastectomy, declared they got it all, and sent her home. She had a follow-up appointment one week later and nothing more than bloodwork scheduled for 6 months. During this time my mother was in a minor car accident that broke her left thumb and right wrist. Before going in to put pins in her wrist, the doctor ordered a routine chest x-ray and they found spots on her bones.

The oncologist verified the cancer had metastasized to the bones. It was in the vertebrae in her neck, middle of her back, left ribs and hip. The oncologist gave her a year to live. They scheduled her for chemotherapy and radiation treatments immedietly to possibly buy her a few more weeks or months. I received a call from my mother the next day giving me her prognosis. She wasn’t ready to die and asked me to help her learn how to live. I quit my job working in the auto parts industry that day. This was my starting point for learning about nutrition, alternative therapies and the whole body approach to healing.

During the next 45 days I read more than 30 books individuals had written that had healed themselves of cancer using alternative methods. I continue to call that time my “crash course” on nutrition and cancer. With each book we revised my mothers dietary regimen and supplemental intake using the information we had learned. Mom was not always at her best and she would often eat things that were on the bad lists we had created. I continued to read and learn, trying anything that had seemed promising from the research material. In the end, they had put so many toxins into her that they had compromised her immune system. She was given so much radiation that they had destroyed the bone mass in her neck. I was told it was a miracle that she was not a paraplegic.

Mom caught an infection from another patient who sat next to her during chemo and two days later she was checked into the hospital. She walked in but that would be the last time she stood. I fought the system from the nutritionist to the doctors, even getting approval for her to not only take her herbals, supplements and teas.…. but they were actually administering them to her while in the hospital.

When they released her from the hospital nine weeks later she was on mega doses of morphine each day. The doctor had told me my mother would suffocate to death. I told him my God wouldn’t do that to me. After one week at home using a soy bean juice product she was pain-free and off all morphine. She had started regaining her quality of life, and the tumors had begun to shrink when two weeks later, on Sept. 14, 1996, she went to sleep and never woke up. In the end my mother lived three years longer than the doctors had given her.

Since then my aunt has fought breast cancer. She continues to stay in remission twelve years later. Also, my best friend Debbie had been diagnosed with liver and colon cancer and had only been given a 5% chance she might survive 2 years. She did a very aggressive regimen because of her medical history and poor prognosis. Six weeks later her body had healed itself and the doctors declared she was in complete remission. This was the starting point for me.

Now, twelve years later, I have worked with thousands of people with cancer as well as numerous other health conditions including my uncle who is currently fighting rectal cancer that had metastisized. He is currently using an all natural supplement that I am working with that aids our bodies in releasing natural killer (NK) cells. He has seen tremendous benefits with his health and we are looking forward to the day that he will get clear test results.

I believe that diet along with nutritional products are the foundation that helps all the other therapies work even better. I feel they are the best offense for keeping my body healthy and my immune system strong. I pray that God will continue to lead those with debilitating illnesses and cancer into my path. I used to pray that if I could just keep one person from having to walk down the path I had to with my mother I would feel blessed. Now I pray for more and more to be healed and feel blessed one hundred times over. I feel it is truly a blessing to know that you can help someone to change their lives in such a positive manner, they can even regain their health. I have shed so many tears these last few years, but they were tears of joy.

This is my prayer for each and every one of you… when you experience the benefits of good health, share the good news with others, get inspired as I am to go out and tell the world your story. Blessings.

Sincerely,
Jacki Smith
Alternative Health Consultant
817.510.3600       
askjacki@gmail.com
http://www.stemcellhotline.com